Natco Pharma Limited
received the final approval of Abbreviated New Drug Application (ANDA) from the US Food and Drug Administration (USFDA) for Bosentan tablets in the strengths of 62.5 mg and 125 mg.
Bosentan is used for the treatment of patients with pulmonary arterial hypertension, the company said in the filing.
The tablets of Natco are marketed by its partner Lupin and are a generic version of Actelion Pharmaceuticals Ltd’s Tracleer tablets in the same strengths.
"As stated by our partner, Lupin, as per IQVIA MAT March 2019 data, Bosentan tablets 62.5 mg and 125 mg had an annual sale of around $84.8mn in the US market", the company added.
Natco Pharma Ltd is currently trading at Rs540.20 down by Rs3.95 or 0.73% from its previous closing of Rs544.15 on the BSE.
The scrip opened at Rs549 and has touched a high and low of Rs553.95 and Rs538.75 respectively. So far 1,75,461 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs9,951.66cr.